NEW IPO ALERT: GenFlow BioSciences – A Disruptive Biotech Company at the Cutting Edge of Longevity Pharmaceuticals

Clear Capital Markets is pleased to announce their involvement with the upcoming IPO of an exciting and fast-growing biotech company working on medication to slow the ageing process in humans.


Genflow Biosciences plc is a UK based biotech company with R&D facilities in Belgium and a US office in Cambridge, MA, driven by one mission: to deliver therapeutics that potentially halt or slow the ageing process in humans and dogs. The company’s lead compound works through the delivery of a centenarian variant of the SIRT6 gene and has yielded promising preclinical results.


Genflow BioSciences will be the first Longevity company to list in Europe.


If you would like to learn more about how you can gain access to this exclusive IPO, fill out the short form and a member of our friendly and experienced team will contact you with further information.

Book Your Review Today

Request more information on GenFlow BioSciences today by Completing this short form

    By Submitting the form you agree to be contacted by Clear Capital Markets with relevant Offers and promotions

    Hear what our clients have to say

    i have been with clear capital for close to 3 years . very happy with the service and the advise given to date – easy to deal with, polite and good at keeping me informed of investment decisions and overall communications

    Sara Rey

    Clear Capital have enabled me to develop an extensive share portfolio which, with their expertise and knowledge continues to deliver profitable returns

    Robert Howett

    I thoroughly recommend Clear Capital Markets. Fantastic range of investment strategies, great knowledge and very importantly superb results!

    Paul Thatcher

    A great firm to deal with. The team work in and out of office hours to get deals over the line, providing great intellect and a breadth of opportunities. Would highly recommend.

    Michael Cripps

    Excellent service both in terms of advisory and execution, the team is very competent and responsive. Outstanding risk management approach.

    Lorenzo Aloe

    Risk Warning

    Trading in equities may not be suitable for all investors.  The value of investments may fall, and you may get back less than you invested.  An investment’s past performance is not a guarantee of future performance.  Investments in pre-IPO’s and IPO’s involve a high degree of risk and are not suitable for all investors.  Small Cap companies can be volatile are considered high risk investments.  Capital invested is at risk.

    Tax allowances depend on your personal circumstances.  Before you trade you should obtain details of all commissions and charges.  You should make sure you can afford any potential losses before you trade.  Make sure you fully understand the risk involved and if you are in any doubt seek independent professional financial advice.

    Clear Capital Markets of Broadgate Tower, 12th Floor, Office 1213, 20 Primrose Street, London, EC2A 2EW are authorised and regulated by the Financial Conduct Authority No. 706689.